Drug Type Monoclonal antibody |
Synonyms SM17单克隆抗体, SM17 |
Target |
Action modulators, inhibitors |
Mechanism IL-25 modulators(interleukin 25 modulators), IL17RB inhibitors(Interleukin-17 receptor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 2 | China | 05 Apr 2026 | |
| Moderate Atopic Dermatitis | Phase 2 | China | 28 Feb 2026 | |
| Severe Atopic Dermatitis | Phase 2 | China | 28 Feb 2026 | |
| Inflammatory Bowel Diseases | Phase 1 | China | 14 Oct 2025 | |
| Asthma | Phase 1 | United States | 14 Jun 2022 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | China | 10 Jan 2019 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | United Kingdom | 10 Jan 2019 |
Phase 1 | - | - | rgtozirrrj(qdsabfmilw) = likkcfdkfg opdomeykqu (xlhxvhzvwr ) View more | Positive | 14 Oct 2025 |






